Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
Status:
Completed
Trial end date:
2009-03-11
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, single sequence, crossover study to be conducted in healthy
adult subjects. There will be a screening visit, three treatment periods, and a follow-up
visit. In Period 1, subjects will receive a single dose of eltrombopag on Day 1, and PK
sampling will occur for 72 hours. In Period 2, subjects will receive LPV/RTV for 14 days with
PK sampling for 12 hours. In Period 3, subjects will receive a single dose of eltrombopag
with LPV/RTV on Day 1 only with PK sampling for 72 hours. Subjects will return for a
follow-up visit within 10 to 14 days of the last dose of study drugs.